A dietary supplement, for use with from 61.3 to 123 grams of dried skimmed milk (or the equivalent quantity of liquid skimmed milk) in the dietary regime disclosed in copending Application Serial No. 338,257 (U.S. Pat. No. 4,009,265), in which the amount of said supplement which contains a datum level of 18.+-.9 mg iron also contains at least 182 mg sodium, at least 308 mg potassium and at least 64 mg magnesium, as well as Vitamin A in an amount of at least 750 .mu.g retinol equivalents, at least 100 i.u. Vitamin D, at least 0.76 mg thiamine, at least 14 mg nicotinic acid (or nicotinamide), and at least 18 mg ascorbic acid, and in which the total calorie content (if any) of that amount of supplement is not greater than 200 Kcals , usually is less than 100 Kcalories, and preferably does not exceed 25 Kcalories. The supplement preferably also contains 50-150 .mu.g iodine and/or at least 157 mg phosporus, and/or traces of copper, zinc and manganese, and/or at least 2 mg Vitamin B.sub.6, at least 5 .mu.g Vitamin B.sub.12, at least 30 i.u. Vitamin E, at least 0.4 mg folic acid and at least 0.7 mg riboflavin. It also desirably contains trace amounts of pantothenic acid, d-biotin, p-aminoenzoic acid, choline and/or Vitamin K, as well as optionally up to 500 mg of L-methionine and/or L-cysteine and/or L-cystine, and/or from 1.0 g to 10 g of essential fatty acid(s).

Dietary supplement and dietary methods employing said supplement for the treatment of obesity

Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, such as Onaway, Russet Burbank, Purple Valley or Bora Valley cultivars. These cultivars and combinations thereof provide a useful antioxidant source enriched in ferulic acid, caffeic acid, chlorogenic acids, ascorbic acid, anthocyanins, and rutin, isomers or derivatives thereof having antioxidant and/or anti-inflammatory activity.

The Royal Institution For The Advancement Of Learning/McGill University

THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

Methods for treating type-2 diabetes and obesity

Disclosed herein are dietary lipid digestion-absorption inhibitory agents and ingesta, comprising as an active ingredient a mixture of chitosan and ascorbic acid or a salt thereof. Also disclosed is a therapeutic method for obesity, which comprises administering an effective amount of a mixture of chitosan and ascorbic acid or salt thereof to a person who requires treatment for obesity.

Kirin Beer Kabushiki Kaisha

Dietary lipid digestion-absorption inhibitory agents and ingesta

An oral composition, suitable as a hypoglycemic agent, includes an isolate from the leaves of Gymnema sylvestre, having a specified molecular weight. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient can be regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, in combination with a non-metabolizable, water-swellable polysaccharide such as the exudate of Sterculia urens, and a water-soluble polysaccharide such as guar gum. Optionally, the present oral compositions can include a physiologically acceptable calcium source, a physiologically acceptable metal carbonate salt, a physiologically acceptable chromium salt, and/or a physiologically acceptable vanadium compound. In addition, antioxidants such as ascorbic acid, cholecalciferol, d-.alpha.-tocopherol, the carotenoids, lycopene, lutein, and the like, can be included as well. The present compositions are useful for amelioration of cholesterolemia, obesity, chronic complications of diabetes and prophylaxis for patients predisposed to the foregoing.

ascorbic acid/obesity

Dietary supplement and dietary methods employing said supplement for the treatment of obesity

Methods for treating type-2 diabetes and obesity

Dietary lipid digestion-absorption inhibitory agents and ingesta

Dietary lipid digestion-absorption inhibitory agents and ingesta

Therapeutic compositions

Baz done ki pi konplè remèd fèy medsin te apiye nan syans